Rakuten Takes Photoimmunotherapy Into Global Phase III Program For Head/Neck Cancer

 
• By Lisa Takagi
  
Rakuten head and neck cancer p3
Rakuten aims to enrol more than 400 patients in its global P3. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Business